Literature DB >> 1697921

Interferon production in sickle cell disease.

S C Taylor1, S J Shacks, S M Villicana, J Olivares, G A Dinkins.   

Abstract

There is limited data on cytokine production in sickle cell disease (SCD). In this study, both alpha (Poly IC-induced) and gamma (PHA-induced) interferon (IFN) were measured in 62 SCD steady state patients, and 21 in the crisis state associated with infections. Comparable normal controls (30 healthy and 14 with infections) were assessed in a similar manner. Gamma IFN production in both SCD groups, steady state (35 +/- 6 U/ml) and crisis state (24 +/- 11 U/ml) was significantly diminished when compared to the normal healthy controls (65 +/- 14 U/ml) with P less than .005. Both SCD groups were also less than normals with infections (56 +/- 23 U/ml) with P less than .005. On closer analysis of individual titers, 15/62 (24%) in the steady state, 11/21 (52%) of SCD patients with infection and 2/14 (14%) of normals with infection, showed impaired gamma IFN when compared to normals without infection (range 27-2187 U/ml). Alpha IFN production in the SCD groups; steady state (512 +/- 113 U/ml) and SCD crisis with infection (559 +/- 110 U/ml) was virtually equivalent to normals (524 +/- 170 U/ml) and normals with infection (509 +/- 116 U/ml). Analysis of individual titers, in contrast to gamma IFN, also showed no significant differences. These results indicate that a significant percentage of SCD patients in both the steady state and infectious state associated with crisis, have impaired gamma IFN production. In view of the known immunomodulatory functions of gamma IFN, this apparent defect may be another factor to explain the increased frequency and severity of infections in SCD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697921

Source DB:  PubMed          Journal:  Lymphokine Res        ISSN: 0277-6766


  7 in total

1.  Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease.

Authors:  Jacqueline M Hibbert; Lewis L Hsu; Sam J Bhathena; Ikovwa Irune; Bismark Sarfo; Melissa S Creary; Beatrice E Gee; Ali I Mohamed; Iris D Buchanan; Ahmad Al-Mahmoud; Jonathan K Stiles
Journal:  Exp Biol Med (Maywood)       Date:  2005-01

2.  High levels of neopterin and interleukin-3 in sickle cell disease patients.

Authors:  L Rodrigues; F F Costa; S T O Saad; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  In vivo production of type 1 cytokines in healthy sickle cell disease patients.

Authors:  S C Taylor; S J Shacks; Z Qu
Journal:  J Natl Med Assoc       Date:  1999-11       Impact factor: 1.798

4.  Type 2 cytokine serum levels in healthy sickle cell disease patients.

Authors:  S C Taylor; S J Shacks; Z Qu; P Wiley
Journal:  J Natl Med Assoc       Date:  1997-11       Impact factor: 1.798

Review 5.  Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.

Authors:  Emmanuel Balandya; Teri Reynolds; Stephen Obaro; Julie Makani
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

6.  Combined effects of in vitro penicillin and sickle cell disease sera on normal lymphocyte functions.

Authors:  Stephen C Taylor; Samuel J Shacks; Zengwei Qu; Psyhra Bryant
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

7.  Baseline and Disease-Induced Transcriptional Profiles in Children with Sickle Cell Disease.

Authors:  Susan Creary; Chandra L Shrestha; Kavitha Kotha; Abena Minta; James Fitch; Lisa Jaramillo; Shuzhong Zhang; Swaroop Pinto; Rohan Thompson; Octavio Ramilo; Peter White; Asuncion Mejias; Benjamin T Kopp
Journal:  Sci Rep       Date:  2020-06-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.